
    
      This is open-label, single-arm, phase II research study, studying the combination of
      cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another
      term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal
      tract, lungs, or thymus.

        -  The research study procedures include screening for eligibility and study treatment
           including evaluations and follow up visits.

        -  Cabozantinib will be administered orally, once daily

        -  Nivolumab will be administered intravenously, every two weeks

        -  The target enrollment for this study is 35 participants.

        -  The U.S. Food and Drug Administration (FDA) has not approved cabozantinib or nivolumab
           for treating carcinoid tumors.
    
  